Warning: session_start() [function.session-start]: Cannot send session cookie - headers already sent by (output started at /usr/www/users/asgt/asgct.org/media/news-releases/index.php:2) in /usr/www/users/asgt/asgct.org/_include/edibo/auth.php on line 2

Warning: session_start() [function.session-start]: Cannot send session cache limiter - headers already sent (output started at /usr/www/users/asgt/asgct.org/media/news-releases/index.php:2) in /usr/www/users/asgt/asgct.org/_include/edibo/auth.php on line 2
Media Information | ASGCT - American Society of Gene & Cell Therapy
About the Society  |  Facebook  |  Contact Us  |  Site Map
ASGCT Press Release
EMBARGOED FOR RELEASE ON
MAY 20, 2010
Contact: Kimberly Jahnke
(414) 278-1341 (Office)
   
ASGCT 13th Annual Meeting:
IV Is Key for Treatment of Advanced Cancers

WASHINGTON – Intravenous delivery of a cancer-targeting virus is successful in destroying cancer cells that have spread throughout the body, according to research to be presented at the American Society of Gene & Cell Therapy 13th Annual Meeting.

A recent study tested 23 patients with metastasized colorectal, skin, ovarian and lung cancers. Patients received a single intravenous treatment at one of five dose levels. In 75 percent of patients who received the highest doses, the therapy reached and replicated within tumors throughout the body, effectively stopping cancer growth. Some patients on the lower doses also saw disease stabilization.

All dose levels were well tolerated, with patients experiencing only mild side effects, such as flu-like symptoms.

“This is the first time that we’ve been able to treat patients intravenously and had proven success in targeting and destroying metastatic cancers in the body with an armed oncolytic virus product,” said David H. Kirn, MD. “This opens up a whole new world of systemic approaches to therapy.”

Gene therapy has been used before to fight cancer, but previous treatments were limited to localized tumors. Intravenous delivery allows for whole-body treatment.

The study results will be presented at 2 p.m. Thursday, May 20.

Members of the media interested in attending the ASGCT Annual Meeting should download the press registration form at www.asgct.org/am10.

Kirn said the study opens the door to retest existing genetic or protein treatments that had previously been limited to patients with localized tumors. Researchers will begin a Phase III trial later this year in patients with liver cancer.

Abstract: 33
Title: Demonstration of Delivery and Antitumoral Activity of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, Following a Single Intravenous Infusion in Patients with Refractory Metastatic Cancers
Date: Thursday, May 20, 2010
Session Info: Simultaneous Oral Abstract Sessions: Cancer-Oncolytic Viruses (2 - 4 p.m.)
Presentation Time: 2 p.m.
Room: Marriott Ballroom, Salon 1

The American Society of Gene & Cell Therapy (ASGCT) is a professional non-profit medical and scientific organization dedicated to the understanding, development and application of genetic and cellular therapies and the promotion of professional and public education in the field. For more information on ASGCT, visit its website, www.asgct.org.

# # #